Regulation of cost-effectiveness claims based on consumer sophistication suggested by CDRH's Burlington.
This article was originally published in The Gray Sheet
Executive Summary
REGULATION OF COST-EFFECTIVENESS CLAIMS BASED ON CONSUMER SOPHISTICATION LEVEL suggested by FDA Center for Devices and Radiological Health Director Bruce Burlington at a Nov. 8 ECRI healthcare technology assessment conference in Plymouth Meeting, Pennsylvania. "One of the ideas that [FDA] currently [is] considering" for regulation of cost-effectiveness claims, Burlington said, is trying to "accommodate the fact that audiences can be reasonably stratified according to their sophistication."
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.